

Dear

**FREEDOM OF INFORMATION – CANCER PRESCRIBING**

I write in response to your request for information in relation to cancer prescribing.

Question:

1. Does your trust treat Polycythaemia Vera (ICD10 code D45)? If no, please provide the name of the trust that you refer Polycythaemia Vera patients to?

Answer:  
Yes

Question:

2. How many patients were initiated on Ruxolitinib (Jakavi) in the past 6 months for the following conditions? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)

Answer:

2a	Myelofibrosis (ICD10 code D47.4)	8
2b	Polycythaemia Vera (ICD10 code D45)	13
2c	Graft vs Host Disease (GvHD) (ICD10 code T86.0 or D89.8) (SNOMED Code: SCTID: 234646005)	5<

Question:

3. How many patients were initiated with the following regimens for any condition in the past 6 months? (Patients are classed as initiated if they have not received any of the above treatments in the previous 6 months)

Answer:

3a	Momelotinib	5<
3b	Fedratinib	Nil

Question:

4. How many patients were treated in the past 6 months for Polycythaemia Vera (ICD10 code D45) with?

Answer:

4a	Hydroxycarbamide*	39
4b	Interferon therapy	14

*\*Please note that some patients are prescribed Hydroxycarbamide via primary care therefore these numbers will not show on our reporting tool.*

Question:

5. Of the myelofibrosis (ICD10 D47.4) patients receiving the following treatments in the past 6 months, please indicate how many were receiving their first systemic therapy  
(*First systemic therapy = patient has not previously received any drug treatment for myelofibrosis, including hydroxycarbamide, interferon therapy, JAK inhibitors, or other systemic therapy. Excludes a watch and wait approach.*)

Answer:

Treatment	First systemic therapy	Received prior systemic therapy
Ruxolitinib (Jakavi)	Nil	Nil
Fedratinib (Inrebic)	5<	Nil
Momelotinib (Omjjara)	8	Nil

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.



If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive